Table 2.
Correlation of baseline EIF3B with Ph− ALL patients’ clinical characteristics and outcomes.
| Items | Baseline EIF3B expression* | P value | |||
|---|---|---|---|---|---|
| Q1 (0-25%, n = 19) | Q2 (25-50%, n = 19) | Q3 (50-75%, n = 19) | Q4 (75-100%, n = 19) | ||
| Demographics | |||||
| Age (years), mean ± SD | 32.6 ± 7.4 | 31.3 ± 9.4 | 30.2 ± 8.3 | 34.8 ± 13.9 | .777 |
| Gender, No. (%) | .607 | ||||
| Female | 9 (47.4) | 8 (42.1) | 9 (47.4) | 7 (36.8) | |
| Male | 10 (52.6) | 11 (57.9) | 10 (52.6) | 12 (63.2) | |
| Immunophenotype, No. (%) | .763 | ||||
| T-ALL | 2 (10.5) | 2 (10.5) | 4 (21.1) | 2 (10.5) | |
| B-ALL | 17 (89.5) | 17 (89.5) | 15 (78.9) | 17 (89.5) | |
| CNSL, No. (%) | .064 | ||||
| No | 19 (100.0) | 18 (94.7) | 18 (94.7) | 16 (84.2) | |
| Yes | 0 (0.0) | 1 (5.3) | 1 (5.3) | 3 (15.8) | |
| Laboratory index | |||||
| WBC ( × 109/L), median (IQR) | 14.6 (10.5-24.7) | 13.0 (9.5-29.5) | 26.2 (11.3-56.3) | 38.4 (21.1-62.9) | .002 |
| HGB (g/L), median (IQR) | 92.8 (72.2-108.0) | 94.1 (77.9-126.8) | 89.7 (68.1-98.5) | 67.3 (60.7-108.5) | .212 |
| PLT ( × 109/L), median (IQR) | 63.7 (31.5-82.3) | 49.2 (17.4-89.4) | 48.2 (27.6-81.9) | 33.9 (18.9-70.6) | .284 |
| Bone marrow blasts (%), median (IQR) | 72.8 (61.9-82.3) | 78.2 (59.6-85.4) | 81.6 (69.4-88.6) | 88.2 (71.3-93.4) | .007 |
| Outcome | |||||
| CR within 4 weeks, No. (%) | .028 | ||||
| No | 3 (15.8) | 5 (26.3) | 7 (36.8) | 9 (47.4) | |
| Yes | 16 (84.2) | 14 (73.7) | 12 (63.2) | 10 (52.6) | |
| Total CR, No. (%) | .060 | ||||
| No | 1 (5.3) | 2 (10.5) | 3 (15.8) | 5 (26.3) | |
| Yes | 18 (94.7) | 17 (89.5) | 16 (84.2) | 14 (73.7) | |
| Allo-HSCT, No. (%) | 0.043 | ||||
| No | 9 (47.4) | 12 (63.2) | 13 (68.4) | 15 (78.9) | |
| Yes | 10 (52.6) | 7 (36.8) | 6 (31.6) | 4 (21.1) | |
Correlation was determined by Spearman's rank correlation test or χ2 test for trend. * Q1: quartile 1, Q2: quartile 2, Q3: quartile 3, Q4: quartile 4. EIF3B, eukaryotic translation initiation factor 3 subunit B; Ph−, Philadelphia chromosome negative; ALL, acute lymphoblastic leukemia; SD, standard deviation; CNSL, central nervous system leukemia; WBC, white blood cell; IQR, interquartile range; HGB, hemoglobin; PLT, platelet; CR, complete remission; Allo-HSCT, allogeneic hematopoietic stem cell transplantation.